I like the structure on this, small up front, just $11MM, but they can trade milestones for higher royalty going into phase III, but no clinical development cost responsibilities like IMGN would have with BT. Overall, this is good for ADC's since it shows continued interest.
According to the IV posters the last presentation went better, but I have not listened to it. Anyone know when IMGN will present some new human clinical efficacy data (more than just a few patients) from the pipeline?
their only goal should be to max shareholder value always. They have never had a successful phase II trial result, so yes they have a very long way to go still after 25 years. Exciting times!
No Q & A I guess, that's where his story/presentation typically falls apart . He can't think on his feet, but like Obama he can read the teleprompter. Up on a day when Dan is presenting is a win!
yes. sounds like alot going on behind the scenes. Dan did mention that their goal is to become a fully integrated pharmaceutical so they have big shoes to fill and a long way to grow.
Must have added too soon again. They might bring this down below 11 before options expiration again.
Has the company closed for the summer, maybe the past 2 years (except R&D)? Someone should inform them (CEO, IR) that No news is Not good news in the development stage biotech industry. No news is better than news of another Phase II failure, or tox issues, but really, it's been 25 years; can we get a product through phase II successfully without Roche??? How about some early human trial data, some news of efficacy/signs of life? WTH is going on over there?
WOW again, 979,000 shares transacted in "market to close" order. Could be positive! I like that it went for 12.01 rather than 11.99, since there was clearly fighting in the last 3 min between a 35000 buy order and a 20,000 sell order at 11.99 and 12.00
Thought I replied, but yes I am holding EXAS. Thank you very much for that recommendation. I wouldn't have known about it otherwise. I got in at 17.59.